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Intravesical bacillus Calmette–Guerin (BCG) is a treatment for transitional cell carcinoma (TCC) and carcinoma in situ (cis) of the
urinary bladder, but some patients remain refractory. The mechanism of cancer clearance is not known, but T cells are thought to
play a contributory role. Tissue dendritic cells (DCs) are known to initiate antigen-specific immune responses following activation of
receptors, which recognise molecular patterns on the surface of microorganisms. A family of these receptors, the toll-like receptors
(TLRs), are also crucial for activating DC to produce cytokines that polarise the T-cell response towards a T helper (Th)1 or Th2
phenotype. This study compared the potential of intact BCG to activate DC with that of the defined TLR4 ligand lipopolysaccharide
(LPS) and the TLR9 ligand CpG-oligonucleotide. It was found that all three stimuli efficiently activated normal DC, but cells expressing
a mutant TLR4 responded poorly to stimulation with LPS. Importantly, stimulation with BCG induced both IL-12 and IL-10, suggesting
subsequent development of a poorly focused T-cell immune response containing both Th1 and Th2 immune function. By contrast,
LPS- and CpG-oligonucleotides induced only IL-12, indicating the potential to produce a Th1 response, which is likely to clear cancer
most efficiently. Given the toxicity of LPS, our data suggest that CpG-oligonucleotides may be beneficial for intravesical therapy of
bladder cancer.
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Bladder cancer is a major health problem, with approximately
12000 new cases diagnosed and 5000 deaths each year in England
and Wales (Cancer Research UK, 2001). Intravesical Mycobacter-
ium bovis bacillus Calmette–Guerin (BCG) has been used as an
ablative treatment for carcinoma in situ (cis) of the bladder since
1976 (Morales et al, 1976) and is now accepted as a bladder-
sparing treatment for cis with an early complete response of 70%;
40% of patients remain disease free after 5 years (Griffiths et al,
2002). Intravesical BCG is also widely used as an adjuvant to
resection for the prophylaxis of recurrent superficial transitional
cell carcinoma (TCC), and may delay progression to invasive
disease (Sylvester et al, 2002). Although BCG has also been
demonstrated to be superior to chemotherapy in a prospective
randomised trial (Lamm et al, 1991; Malmstrom, 2000), 30% of
TCC, including high-stage and muscle-invasive disease fail to
respond. Furthermore, the administration of BCG results in local
and systemic side effects including cystitis, polyarthritis and,
rarely, death. Clearly there is scope to improve this therapy.
Recent work has provided strong evidence that the antitumour
mechanism of BCG therapy is mediated through induction of a
cascade of immunological events and the promotion of acute
inflammation in the urothelium. This immune stimulation may be
mediated through dendritic cells (DCs) that act as potent antigen-
presenting cells and are capable of initiating cancer-directed
immune responses (Jefford et al, 2001; Gabrilovich, 2002).
Dendritic cell activation in response to BCG is mediated by a
family of innate immune receptors called toll-like receptors
(TLRs), which recognise pathogen-associated microbial products
(Medzhitov, 2001). Toll-like receptors signal through the intracel-
lular MAPK and NFkB pathway cascades to induce inflammatory
cytokine secretion, induction of DC antigen presentation state and
T-cell stimulation. Hence, ligation and signalling through TLRs
can shape the developing immune response.
Effective BCG therapy requires induction of a T-cell-mediated
immune response (Ratliff et al, 1987; Ratliff, 1992) and the
activation of a natural killer (NK) cell-like population with an
apparent ability to distinguish between normal and cancer cells
(Bohle et al, 1993; Brandau et al, 2001). Significantly, both T-cell-
and NK-cell-deficient mice respond poorly to BCG therapy
(Brandau et al, 2001). Following BCG instillation, it has been
shown that there is an accumulation of immunocompetent cells
into the bladder wall including activated T helper (Th) lympho-
cytes, NK cells and DCs; adhesion molecules (ICAMs) and
costimulatory B7 antigens are also upregulated (Patard et al,
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s1996; Saint et al, 2001). These activated effector cells kill target cells
by production of nonspecific soluble factors and by direct cell-to-
cell contact.
Many cytokines are detectable in the urine following BCG
therapy, including IL-1, IL-2, IL-6, IL-7, IL-10, IL-12, interferon-
inducible protein 10, TNFa, IFNg and a number of chemokines
(Jackson et al, 1995; Patard et al, 1998; Taniguchi et al, 1999). This
range of cytokines indicates the activity of mutually antagonistic
Th1-type and Th2-type immune processes with no evidence of
polarisation of the response to a tissue-destructive and potentially
more beneficial Th1 (or delayed type hypersensitivity; DTH)
phenotype.
Importantly, animals with deletion of IL-12 or IFNg are resistant
to BCG immunotherapy and die rapidly from experimental bladder
cancer (Riemensberger et al, 2002), while supplementing BCG with
these characteristic Th1 cytokines can enhance cancer clearance
(O’Donnell et al, 1999). By contrast, the production of immuno-
suppressive IL-10 during BCG therapy reduces inflammation and
the anticancer response (Nadler et al, 2003). On this basis, we
postulate that the immune response elicited by BCG is suboptimal
and potentially antagonistic, and might limit the survival of some
patients with bladder cancer. Furthermore, poor polarisation of the
phenotype of the Th response may allow tumour-immune escape,
suggesting a possible mechanism for BCG treatment failure.
In this report, we demonstrate that BCG stimulates cultured
murine DCs to produce cytokines that potentially elicit a
suboptimal, mixed Th1 and Th2 immune response. Moreover, in
contrast to lipopolysaccharide (LPS), BCG is still able to stimulate
the production of both Th1- and Th2-promoting cytokines by
cultured DCs from TLR4-mutant mice. Significantly, we also show
that stimulation of DCs with unmethylated CpG-motif containing
oligonucleotides, a known ligand for TLR9, results in the
production of IL-12 but not IL-10, suggesting that these agents
polarise the immune response towards an antitumour Th1
phenotype. We suggest that CpG-oligonucleotides could have
potential as immunotherapy agents in patients with bladder
cancer.
MATERIALS and METHODS
Animals
Female C3H/HeSn (TLR4 wild type, LPS responsive) and C3H/HeJ
(TLR4 mutant, LPS resistant) mice (8–10 weeks old) were
purchased from Charles River UK (Kent, UK). Female CD1 mice
(8–10 weeks old) were purchased from Harlan UK (Oxon, UK). All
mice were used in accordance with UK Home Office License
(PPL60/2610).
Generation of DCs from murine bone marrow
Femurs and tibiae were removed from mice following killing.
Bones were sterilised by brief washing in 70% (vv
 1) ethanol and
the marrow flushed out using complete medium (RPMI-1640
supplemented with 10% (wv
 1) foetal bovine serum, 100Uml
 1
penicillin and 100mgml
 1 streptomycin and 2mML -glutamine
(Sigma, Dorset, UK) using a 21-gauge needle attached to a 1ml
syringe. Following centrifugation, red blood cells were lysed by
washing in 0.15 M ammonium chloride, 0.01mM EDTA, 10mM
sodium bicarbonate. After further centrifugation, cell clusters were
disassociated by vigorous syringing. Approximately 1–1.5 10
7
leucocytes were obtained from each C3H mouse. Cells were
resuspended in complete medium and seeded into either 24- or
six-well tissue culture plates at a seeding density of 2 10
5 or
2 10
6 cellswell
 1, respectively. These cultures were supplemen-
ted with 10ngml
 1 recombinant murine GM-CSF with or without
10ngml
 1 recombinant murine IL-4 (PeproTech EC, London, UK)
and incubated at 371C in a humidified atmosphere containing 5%
(vv
 1)C O 2 for 7 days. On the third and fifth days of culture, 0.5 or
1ml of medium was removed from each well of a 24- or six-well
plate, respectively, and replaced with medium containing fresh
cytokines. Fresh medium and cytokines were also added prior to
all stimulations.
Cell surface marker analysis by flow cytometry
Dendritic cells were examined by flow cytometry to verify their
phenotype before and following activating stimuli. In all, 2 10
5
cells were harvested and resuspended in PBS containing 5% (vv
 1)
FCS and examined for CD83 and CD86 expression by staining with
monoclonal antibodies to CD83 (fluorescein isothiocyanate (FITC)
conjugate, clone Michel17, rat IgG1, Biocarta, UK) and CD86 (B7-
2, phycoerythrin (PE)-conjugated clone RMMP-2, rat IgG2a,
Caltag, UK). Unstained cells were included as negative controls
in each labelling experiment. Stained cells were analysed by flow
cytometry (FACSort; Becton Dickenson, Cowley, UK). Data
analysis was performed using FACs express software (DeNovo
Software, Ontario, Canada).
Endocytosis assay
Dendritic cell cultures were incubated with 1mgml
 1 of FITC-
labelled dextran (MW 70000, Sigma) for 60min at either 37 or 41C.
Dendritic cells were harvested and washed three times in PBS
containing 1% (vv
 1) FCS and 0.01% (wv
 1) sodium azide
(NaN3). FITC-dextran uptake was analysed by FACs.
Stimulation of DCs with BCG, LPS and
CpG-oligonucleotides
Dendritic cell cultures (7 days old) were provided with fresh RPMI-
1640 culture medium containing fresh cytokines (10ngml
 1 GM-
CSF, 10ngml
 1 IL-4); experimental wells were further supplemen-
ted with TLR ligands. These activating ligands were 50 or
100ngml
 1 LPS (Sigma), 1.25 10
5 colony forming units
(CFU)ml
 1 BCG (ImmuCystt, Connaught strain, Pasteur Merieux
Connaught, Canada), 2 or 5mM phosphorothioate-stabilised CpG-
rich adjuvant oligonucleotide (ODN) (containing CG motif, ATA
ATC GAC GTT CAA GCA AG; TAG, Newcastle, UK) or 2mM
phosphorothioate stabilised non-CpG-rich control-ODN (reversed
CG motif, ATA ATG CAG CTT CAA GCA AG; TAG Newcastle).
The use of CpG-rich and non-CpG-rich ODN sequences has been
described previously (Chu et al, 1997). All DC cultures were
stimulated at 371C for 72h.
Measurement of DC cytokine profiles by ELISA
Following stimulation with activating ligands, DC-conditioned
media were collected and frozen at  201C prior to analysis. The
presence of IL-12 and IL-10 was measured by ELISA (murine IL-12
ELISA development kit, PeproTech EC, IL-10 eBioscience, San
Diego, CA, USA). The results are presented as means7s.e. from
duplicate analysis.
Isolation of splenic lymphocytes
Mononuclear cells were isolated from allogenic mouse spleens
using gradient separation and plastic-adherence depletion. Briefly,
the spleens from CD1 mice were removed and passed through a
70mM nylon cell strainer (BD Falcon) followed by washing in
complete medium. Cells were diluted with complete medium and
underlain with 6ml Histopaquet-1083 (Sigma Diagnostics, USA).
Cells were centrifuged at 400g for 25min with zero break speed.
Mononuclear cells were recovered from the interphase and
monocytes depleted by plastic adherence for 2h. The enriched
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slymphocyte population was washed in complete medium and used
immediately in mixed lymphocyte reaction (MLR) assays.
Measurement of DC-induced T-cell proliferation following
BCG activation by the MLR assay
The functional maturity of stimulated DCs was assessed by
investigation of their capacity to stimulate allogenic T-cell
proliferation within an MLR. Briefly, 7-day-old cultures of both
C3H/HeSn and C3H/HeJ DCs were stimulated with 6.25 10
4 or
1.25 10
5CFUml
 1 BCG. After 72h stimulation, DCs were
irradiated with 25Gray (Gy) g-irradiation to prevent their
proliferation during the course of the MLR. This dose of
irradiation has previously been shown to be sufficient to prevent
DC proliferation (Pettit et al, 2002).
Dendritic cells were added to the wells of a round profile 96-well
plate in halving dilutions to give stimulator cell numbers ranging
from 1 10
5 to 1.25 10
3 cellswell
 1. Responder T cells were
added at 1 10
5 cellswell
 1 such that the stimulator:responder
ratio ranged from 1:1 to 0.125:1. T cell-only control cultures were
also included and repeatedly showed low levels of proliferation. All
cells were plated into complete medium in a total volume of 200ml.
The proliferation of responder cells in each microculture was
determined after 5 days following incubation with 1mCiwell
 1
[3H]thymidine for 6h. Radiolabelled DNA was harvested and
[3H]thymidine incorporation measured using a b-scintillation
counter. Assays were conducted in triplicate for each stimula-
tor:responder ratio.
Statistical analysis
All determinations were performed in triplicate and each result
expressed as the mean7s.e. Statistical significance was determined
by unpaired t-tests. A P-value of 0.05 or less was considered to be
significant.
RESULTS
Characterisation of DCs from mouse bone marrow
progenitors
Murine bone marrow progenitor cells were cultured in GM-CSF
and IL-4 for 7 days to provide a population of DCs. A population
of adherent, granular cells with surface dendrites was visible on
examination by light microscopy (not shown). Flow cytometry was
employed to examine the expression of the DC markers CD83 and
CD86 (B7-2). Representative flow cytometric histograms are shown
(Figure 1A). The expression of these markers was similar in both
C3H/HeSn and C3H/HeJ DC cultures.
Dendritic cell cultures were also examined for their ability to
phagocytose antigen. It has previously been reported that
immature DC phagocytosis can be examined by the in vitro
uptake of dextran molecules. Representative flow cytometric
histograms show fluorescence of DCs after incubation with
FITC-dextran at 371C (Figure 1B). At 01C, very limited uptake of
FITC-dextran and fluorescence was seen (Po0.0001). Uptake of
antigen by C3H/HeSn and C3H/HeJ DCs did not differ significantly
(P¼0.1769). Together, the phenotypic marker expression and
endocytosis assays support the hypothesis that a semimature
population of DC is present using these in vitro culture conditions.
BCG induces phenotypic maturation of DCs
Dendritic cells were examined for phenotypic maturation following
stimulation by activating stimuli. This was determined by
measuring the upregulation of CD83/86 marker expression and
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Figure 1 Flow cytometric plots showing the expression of DC markers CD83 and CD86 (A) and uptake of FITC-dextran (B) by unstimulated C3H/
HeSn DCs.
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sthe downregulation of phagocytosis. Bacillus Calmette–Guerin
stimulation of C3H/HeSn and C3H/HeJ cultures showed no
difference on the maturation status of DC by examination of
CD83 expression (Figure 2A), but did result in a dose-dependent
increase in the expression of CD86 in DCs from both mouse strains
(Figure 2B).
Phenotypic maturation of DCs also results in the downregula-
tion of antigen phagocytosis. A reduction in phagocytosis of FITC-
dextran was observed in DCs from both mouse strains following
72h BCG stimulation compared to nonstimulated control DC
cultures (C3H/HeSn; P¼0.0133, C3H/HeJ; Po0.0001) (Figure 2C).
C3H/HeSn and C3H/HeJ did not differ in their activation and
downmodulation of phagocytosis after BCG stimulation
(P¼0.4334).
Antigen presentation by BCG stimulated DCs
Mixed lymphocyte reaction assays were carried out to assess the
functional antigen-presentation state of DC cultures to induce the
proliferation of resting allogeneic T cells in coculture with BCG
stimulated C3H/HeSn and C3H/HeJ DCs (Figure 3). Bacillus
Calmette–Guerin-stimulated C3H/HeSn and C3H/HeJ DCs have an
increased capacity to induce significant T-cell proliferation at
stimulator: responder ratios of 0.5:1 and below, compared to
nonstimulated DCs (0.5:1, P¼0.0078 and 0.0010, respectively,
0.125:1, P¼0.0175 and 0.0010, respectively). This induction of
proliferation did not differ significantly between C3H/HeSn and
C3H/HeJ DCs (P¼0.1010). No induction of proliferation was
evident at 1:1 stimulator:responder ratio. No proliferation was
observed in control cultures of DC alone, confirming that 25Gy g-
irradiation is sufficient to prevent DC proliferation.
Activation of DCs by BCG produces both Th1- and
Th2-polarising cytokines
Secretion of the Th1-polarising cytokine IL-12 and the Th2-
polarising cytokine IL-10 from C3H DCs stimulated with BCG or
LPS was studied. IL-12 could be detected in culture supernatants
24h after stimulation (data not shown) and after this, no further
increase in cytokine production was observed. IL-12 production
was enhanced by C3H/HeSn DCs in response to both LPS and BCG
compared to nonstimulated control cultures (P¼0.0001 and
0.0006, respectively) (Figure 4A). Stimulation of IL-12 by LPS-
treated C3H/HeSn DCs was significantly greater when IL-4 was
omitted from the culture medium (P¼0.004), whereas stimulation
of IL-12 production by BCG in DCs from this strain was unaffected
by the presence of IL-4 (P¼0.301). The TLR4 mutant C3H/HeJ
DCs also showed enhanced IL-12 production in response to BCG
(Po0.0001) but, as expected, no enhancement of IL-12 production
was observed in response to the TLR4 ligand LPS (P¼0.356)
(Figure 4B).
In DCs from both mouse strains, IL-10 production was
enhanced by BCG (Po0.0001), but not by LPS (P¼0.3829)
(Figure 5). IL-10 production was also dependent on the cytokine
conditions of the DC cultures. The induction of IL-10 was
significantly lower when DCs were cultured in the presence of
both GM-CSF and IL-4 conditions compared to GM-CSF alone
(Po0.0001).
Activation of DCs by CpG-oligonucleotides produces a
polarised Th1 cytokine response
The activation of DCs by phosphorothioate-stabilised, adjuvant
CpG-containing oligonucleotide was also assessed and measured
by cytokine production. Following stimulation of C3H/HeSn DCs
with adjuvant CpG-oligonucleotides, the production of IL-12 was
comparable to that achieved following BCG stimulation and was
highly significant compared to control cultures (Po0.0001)
(Figure 6A). The amount of secreted IL-12 in response to both
BCG or adjuvant CpG did not differ between the two C3H mouse
strains (data not shown). Stimulation of DCs with oligonucleotides
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Figure 2 Expression of CD83 (A), CD86 (B) and uptake of FITC-
dextran (C) by C3H/HeSn and C3H/HeJ DCs following stimulation with
BCG. Dendritic cells were harvested from C3H/HeSn mice (clear bars) and
C3H/HeJ mice (hatched bars) and cultured for 7 days in GM-CSF and IL-4
followed by stimulation with 6.25 10
4 and 1.25 10
5CFUml
 1 BCG for
72h. Expression of markers and FITC-dextran uptake were analysed by
flow cytometry (MEF: median fluorescence; CFU: colony forming units).
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slacking CpG-motifs failed to induce IL-12 production compared to
CpG-containing oligonucleotides (Po0.0001). As with BCG
stimulation, IL-12 production in response to adjuvant CpG-
oligonucleotides was dependent on the in vitro cytokine condi-
tions, with a significantly lower induction of IL-12 in GM-CSF and
IL-4 conditions (Po0.0001).
In contrast to stimulation with BCG, CpG-oligonucleotide
stimulation did not result in IL-10 production in C3H/HeSn DCs
(Figure 6B; Po0.0001). This apparently polarised Th1 response
was even more striking when the DCs were cultured in GM-CSF
and IL-4 rather than GM-CSF alone. A summary of cytokine
production by in vitro DC cultures from both mouse strains
following stimulation with different TLR ligands is given in
Table 1.
DISCUSSION
We have developed a reliable and reproducible method for the
culture and activation of DC from murine bone marrow
progenitors. These cultures display the highly phagocytic pheno-
type characteristic of immature DCs but also express CD83 and
CD86, which are markers of DC maturation. This supports
previous findings that DCs cultured ex vivo are of a semimature
phenotype (Son et al, 2002). Semimature DC phenotypes are
analogous to steady-state migratory veiled DCs within lymphatics
and are thought to tolerise lymph node T cells against tissue-
derived self-antigens or apoptotic cells (Inaba et al, 1998; Lutz and
Schuler, 2002). Such DCs are nonimmunogenic and are distin-
guished as mature by surface marker expression (MHCII
high and
costimulation
high), but have no elevated release of proinflamma-
tory cytokines. They require decisive immunogenic maturation
signals for full maturation and the release of proinflammatory
cytokines. The activation of DCs also results in the down-
modulation of endocytosis and antigen processing, stablisation
of MHC peptide complexes and upregulation of molecules related
to antigen presentation and T-cell costimulation (Fearon and
Locksley, 1996).
Several TLR ligands including BCG, CpG and LPS are potent
stimuli for DC activation and induce both a mature phenotype and
cytokine production. In this study, we have shown that BCG
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Figure 3 Antigen presentation by C3H/HeSn (A) and C3H/HeJ (B)
DCs in the presence and absence of BCG. Functional antigen presentation
was assessed by assessment of murine CD1 T-cell proliferation in an
allogenic MLR. Dendritic cells were cultured for 7 days in the presence of
GMCSF and IL-4, followed by culture for 72h in either the absence of
activating stimuli (clear bars), 6.25 10
4CFUml
 1 BCG (hatched bars) or
1.25 10
5CFUml
 1 BCG (checked bars). Proliferation of T cells was
measured by the incorporation of [3H]thymidine.
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Figure 4 Production of IL-12 by C3H/HeSn (A) and C3H/HeJ (B) DCs
following stimulation with LPS and BCG. Dendritic cells were cultured for 7
days in the presence of GM-CSF only (clear bars) or GM-CSF and IL-4
(hatched bars), followed by 72h stimulation with either LPS or BCG. IL-12
concentration was determined by ELISA.
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sstimulation of DCs induces maturation from a semimature to a
fully mature phenotype, which is evident by downregulation of
phagocytosis and upregulation of the maturation marker CD83
and costimulatory molecule CD86. We have also shown that
phenotypic changes associated with the maturation of DCs are
similar in both C3H/HeSn (TLR4 wild type) and C3H/HeJ (TLR4
mutant) DCs following activation with BCG. Genetic analysis of the
endotoxin hyposensitive mouse C3H/HeJ identified TLR4 as the
primary receptor for LPS (Qureshi et al, 1999). This demonstrates
that BCG activation of antigen presentation by DCs is not
dependent on TLR4 engagement.
No stim
50 ng ml −1  LPS
100 ng ml −1  LPS
250
500
750
1000
I
L
-
1
0
 
p
g
 
m
l
−
1
C3H/HeSn
C3H/Hej
1.5×10 4  CFU ml −1  BCG
 1.25×10 5  CFU ml −1  BCG
No stim
50 ng ml −1  LPS
100 ng ml −1  LPS
1.5×10 4  CFU ml −1  BCG
 1.25×10 5  CFU ml −1  BCG
A
0
250
500
750
1000
I
L
-
1
0
 
p
g
 
m
l
−
1
0
B
Figure 5 Production of IL-10 by C3H/HeSn (A) and C3H/HeJ (B) DCs
following stimulation with LPS and BCG. Dendritic cells were cultured for 7
days in the presence of GM-CSF only (clear bars) or GM-CSF and IL-4
(hatched bars), followed by 72h stimulation with either LPS or BCG. IL-10
concentration was determined by ELISA.
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Figure 6 Production of IL-12 (A) and IL-10 (B) by C3H/HeSn following
stimulation with CpG-oligonucleotides. Dendritic cells were cultured for 7
days in the presence of GM-CSF only (clear bars) or GM-CSF and IL-4
(hatched bars), followed by 72h stimulation with either
1.25 10
5CFUml
 1 BCG, 2 or 4mM adjuvant CpG or 2mm control
oligonucleotide. Cytokine concentration was determined by ELISA.
Table 1 Cytokine production by cultured DCs from TLR4 mutant and
wild-type C3H mice following stimulation by LPS, BCG and CpG-
oligonucleotides
C3H/HeN:
TLR4 wild type/LPS responsive
C3H/HeJ: TLR4
mutant/LPS resistant
IL-12 IL-10 IL-12 IL-10
BCG + + + +
LPS +     
CpG +   +  
DC¼dendritic cells; TLR¼toll-like receptor; LPS¼lipopolysaccharide; BCC¼ba-
bacillus Calmette–Guerin; IL¼interleukin.
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sOur investigations have also shown that BCG stimulation of
murine DC cultures results in the production of a proinflammatory
cytokine milieu, but which is not polarised towards a Th1-inducing
profile. This is evident from the production of both IL-12 (Th1)
and IL-10 (Th2) cytokines. In clinical practice, a burst of urinary
Th1 cytokines IFNg, IL-12 and IL-2 has been observed after BCG
therapy and is a common feature in BCG responders, whereas
higher levels of the Th2 cytokines IL-10 and/or IL-6 appear to be
associated with BCG failure (Esuvaranathan et al, 1995; de Reijke
et al, 1996). Patients who failed BCG immunotherapy also showed
higher antibody responses to BCG heat shock proteins in their sera
(Zlotta et al, 1997). This nonpolarised activation of immune cells
may represent a mechanism for BCG treatment failure in bladder
cancer patients. Thus, it is proposed that efforts to polarise the
immune response by increasing the production of Th1-promoting
IL-12, and diminishing IL-10 will have a therapeutic value. Indeed,
IL-10 deletion studies performed either by antibody inhibition or
using gene knockout animals resulted in enhanced DTH response
and antitumour activity (Nadler et al, 2003), while IL-10 knockout
mice also showed prolonged survival and response in a syngeneic
model of orthotopic bladder cancer (Riemensberger et al, 2002).
This response was shown to coincide with an increased influx of T
and NK cells into the bladder walls of these mice.
Another mechanism for promoting a Th1 immune response
involves the therapeutic use of cytokine combinations to increase
the production of IFNg. O’Donnell et al (1999) reported a striking
increase in IFNg production in cell culture following the addition
of small amounts of recombinant IL-12. This synergistic effect of
IFNg production could also be produced by intravesical admin-
istration of BCG with IL-12, but was downregulated by IL-10
(O’Donnell et al, 1999). The ability of exogenous IL-12 to shift this
balance strongly towards Th1 provides the immunological basis
for combination with BCG for successful bladder cancer therapy.
It has been reported that nonmethylated palindromic DNA
containing CpG-ODN can activate an innate immune response by
activation of NK cells, DC and B cells in an antigen-independent
manner (Weiner et al, 1997). Recognition of these microbial
sequences is mediated by a member of the TLR family, namely
TLR9. CpG-oligonucleotides have been shown to act as adjuvants
to induce the expression of Th1-type cytokines in mouse models
(Chu et al, 1997), and lead to the production of IL-12, IL-18 and
IFNg by peripheral blood mononuclear cells in humans (Bohle
et al, 1999). CpG-ODN have also been used to produce cancer-
antigen-presenting DCs for use in immunotherapy (Brunner et al,
2000). Further studies have shown that peritumoral treatment
resulted in complete rejection or strong inhibition of a variety of
established mouse tumours, including B16 melanoma and 3LL
lung carcinoma, whereas systemic administration only had partial
effects (Kawarada et al, 2001). Heckelsmiller et al (2002) reported
the combined use of CpG and antigen-pulsed DCs to cure large
murine tumours that were resistant to chemotherapy.
Phosphorothioate-stabilised CpG-oligonucleotide sequences ac-
tivate and preferentially elicit Th1 cytokine production by cultured
mouse DCs (Jones et al, 2002). In our studies, we have shown that
CpG-ODN stimulation of murine DC cultures results in the
production of the Th1-polarising cytokine IL-12 at levels compar-
able to those produced by BCG. However, in contrast to BCG, CpG-
oligonucleotides did not result in concurrent production of the
Th2 cytokine IL-10 (Figure 7). An inverted control sequence motif
oligonucleotide failed to stimulate DC cultures to produce a
cytokine response, showing that this effect was sequence specific.
As expected, cytokine production was independent of TLR4 status
as shown by IL-12 production in both C3H/HeSn and C3H/HeJ
DCs. However, although CpG-ODN did induce a polarised Th1
cytokine response, this was dependent on the in vitro culture
cytokine conditions employed. We observed that IL-12 secretion
from DCs was only evident when DCs were cultured in GM-CSF
alone. The presence of the Th2 cytokine IL-4 appeared to inhibit
IL-12 production in response to CpG-ODN stimulation. This
suggests that the Th1-polarising stimulation of DCs by CpG will be
dependent on the local cytokine environment of the DC activation.
The finding that CpG-oligonucleotides can induce IL-12
production in DCs without concurrent production of IL-10
supports our hypothesis that DCs can be polarised to a Th1
immune response and that this can be manipulated to improve the
efficiency of bladder cancer immunotherapy. The potential of
CpG-oligonucleotides as a single agent or combination therapy
with sparing doses of BCG is currently being evaluated in an
orthotopic mouse model of bladder cancer.
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